ReviewFrontiers in oncology2026
Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papulopustular eruption is a characteristic dermatologic toxicity of classical epidermal growth factor receptor (EGFR) inhibitors and may impair quality of life, supportive-care needs, and treatment continuity. Although frequently termed acneiform, it is distinct from acne vulgaris and is better understood as a therapy-associated folliculocentric inflammatory eruption. Related papulopustular phenotypes have been reported with MEK inhibitors and newer EGFR-targeting regimens such as amivantamab, but these settings differ in pharmacology, evidence base, and clinical behavior. This Mini Review summarizes these eruptions across three evidence contexts: classical EGFR inhibitor-associated eruption, MEK inhibitor-associated overlapping eruption, and amivantamab-associated scalp-predominant disease in an EGFR/MET bispecific-antibody setting. We discuss mechanisms using an evidence-tiered approach, distinguishing relatively direct evidence for KLF4/IL-36γ signaling and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.